Novo Nordisk Infographic

Novo Nordisk Is Falling. A Rival Weight-Loss Drug Is on Way.

Novo Nordisk Is Falling. Compeitition Is a Killer.

Novo Nordisk stock was dropping on Wednesday after Roche said it had licensed a promising obesity drug in a deal that could cost it up to $5.3 billion.U.S.-listed shares of Novo Nordisk were down 5.2%.

NBC Chicago · 5d

Novo Nordisk shares fall 6.3% after latest trial results for its next-generation weight loss drug

Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug.

MarketWatch on MSN · 3d

Roche takes big step in weight-loss field with $5.3 billion deal. Novo Nordisk shares fall.

Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to Zealand Pharma in a licensing and development deal.

2don MSN

How a Novo Nordisk Foundation-funded project sparked ultra-processed food fight

The Novo Nordisk Foundation and University of Copenhagen researchers have backtracked over a project to redefine how the ...

Yahoo Finance10d

Novo Nordisk Plunges 21% in 3 Months: Buy, Sell or Hold the Stock?

Novo Nordisk NVO shares have lost 21% in the past three months against the industry’s growth of 4.6%. The company has also underperformed in the sector and the S&P 500 during the same time frame ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Novo Nordisk Is Falling. A Rival Weight-Loss Drug Is on Way.

Trending now